News

Jakavi is the first targeted treatment approved by the EC for these patients in the European Union (EU) who are resistant to or intolerant of hydroxyurea. The European

The MVA Ebola Zaire vaccine candidate is expected to be used in a Phase I clinical trial being supported by a grant from the Wellcome Trust and the

The Canadian group will use Cannigistics’ software and information technology platform to gather, store, analyze and report on the results of the trials. This technology platform will help

The approval allows the new line of products to be distributed in the US into big box retail chain stores as well as facilitate entry into more regulated

Galeterone is being developed to treat castration-resistant prostate cancer (CRPC) that acts by actively disrupting AR signaling, the key driver of prostate cancer growth, via multiple mechanisms of

The supplemental new drug application (sNDA) approval for VIIBRYD expands dosing options available to health care providers when using it to treat MDD in adult patients. The company

The company’s lead drug candidate, ImMucin, targets the less studied Signal Peptide domain of the MUC1 tumor antigen, which harbours key advantages as an anti-MM modality. ImMucin teaches

Valeant’s new offer of $173 a share, is an increase from a bid of $158 per share in cash made this February. The revised share offer, which adds

The study was designed to investigate the effect of adding ticagrelor at 60mg and 90mg to low dose aspirin on reducing the risk of CV death, heart attack